News

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical...

Read more

Upon infection cells manage to quickly switch from normal operation to immune reaction in a matter of minutes. This innate immunity requires a...

Read more

IP Protection for Scarletred®Vision in the EU, USA, Japan and Australia.

Read more
  • Annual general meeting on June 27, 2019 resolved on the delisting of Valneva’s ordinary shares from the Vienna Stock Exchange
  • Delisting shall be...
Read more

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs,...

Read more

Investors provided further €1.5 million in equity investments to support phage therapy to tackle the antibiotics crisis.

Read more

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs,...

Read more

A two-days workshop focused on practical use of bio.tools, a comprehensive registry of research software and databases led by the guest lecturer Radka...

Read more

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs,...

Read more

Nucleic acids and proteins can be described on different structural levels, but all depend on the most basic - the primary structure. It describes the...

Read more

Originally from Turkey, Elif Karagöz’s scientific journey brought her to Germany to do her Master’s and to the Netherlands for her PhD at Utrecht...

Read more